Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-18T17:49:08.550Z Has data issue: false hasContentIssue false
  • English
  • Français

PW01-158 - Differentials Effects Of Olanzapine And Risperidone On Plasma Adiponectin Levels Over Time: A Prospective Study

Published online by Cambridge University Press:  17 April 2020

A. Heald ,
L. Hanssens ,
M. Wampers ,
D. Van Eyck ,
R. van Winkel  and
M. de Hert
A. Heald
Affiliation:
Dept of Medicine, Leighton Hospital, Crewe, UK
L. Hanssens
Affiliation:
Department of Epidemiology and Public Health, University of Liege, Liege, Belgium
M. Wampers
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, Leuvense Steenweg, Belgium
D. Van Eyck
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, Leuvense Steenweg, Belgium
R. van Winkel
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, Leuvense Steenweg, Belgium
M. de Hert
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, Leuvense Steenweg, Belgium

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Recent research has shown that adiponectin levels in patients with schizophrenia vary similar to the general population. Moreover, antipsychotic medication may influence adiponectin levels, independent of metabolic parameters. We hypothesise different antipsychotics might vary in their effect on adiponectin levels independent of BMI and metabolic syndrome (MetS) status.

Methods

113 patients, with similar baseline demographic and metabolic characteristics, received either risperidone (n=54) or olanzapine (n=59). They were followed prospectively for 12 weeks. Adiponectin levels as well as general metabolic parameters were measured at baseline, 6 weeks and 12 weeks.

Results

We observed a significant treatment by time interaction, showing an adiponectin increase in the risperidone treated patients and an adiponectin decrease in olanzapine treated patients. This effect was independent of BMI and the presence/absence of the metabolic syndrome. There was a significant association between fall in adiponectin and increase in waist circumference in the Olanzapine treated group (Figure 1).There was no change in HOMA-IR as a measure of insulin resistance in either group.

Conclusion

We observed a differential effect of antipsychotic treatment (risperidone vs olanzapine) on adiponectin levels over time, independent of BMI (and MetS) suggesting an effect of olanzapine on adipose tissues, similar to what has been observed in animals models. The effects on adiponectin levels may partly explain the increased rates of obesity with Olanzapine.

Type
Others
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E1557
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.